AOD-9604 is a proven fat-loss peptide that retains hGH's lipolytic effect without its diabetogenic side effects.

AOD-9604 is a synthetic 16-amino-acid fragment of human growth hormone, corresponding to residues 177-191 of the C-terminal domain of hGH. The molecule was developed at Monash University in the 1990s by Frank Ng's group and licensed to Metabolic Pharmaceuticals (Melbourne) for clinical development as an anti-obesity therapeutic. The marketing narrative in the recreational peptide community in 2026 still anchors to the preclinical lipolysis story: the fragment retains the lipolytic activity of the parent hGH molecule without the diabetogenic and growth-promoting effects of full-length hGH. That narrative is mechanistically tidy. The clinical-trial story is not.

The Phase 2b that ended the program

Metabolic Pharmaceuticals ran a 24-week placebo-controlled Phase 2b trial enrolling 536 obese adults across multiple Australian sites, completed in 2007. The trial tested five dose arms (1 mg, 5 mg, 10 mg, 30 mg, plus placebo) of daily oral AOD-9604. The primary endpoint was weight reduction at 24 weeks versus placebo. The trial failed its primary endpoint — no statistically significant difference in weight loss between any active dose arm and placebo. The company subsequently announced it would not pursue further weight-loss development of the molecule. The Phase 2b dataset has never been published in a peer-reviewed journal; the public record consists of company press releases and ASX disclosures.

After 2007, the AOD-9604 development program effectively ended for the obesity indication. Metabolic Pharmaceuticals shifted positioning toward osteoarthritis and other indications. The molecule was later granted Generally Recognized As Safe (GRAS) status by the FDA in 2014 for food and supplement applications, based on safety data — not efficacy data. GRAS status is a safety determination; it makes no claim about whether the substance does what it is marketed to do.

What the recreational marketing actually rests on

The "proven fat-loss peptide" framing in 2026 rests on three sources: (1) the preclinical lipolysis data in rodent adipocytes and adipose-tissue homogenates from the 1990s Monash work; (2) a small open-label or uncontrolled clinical series from earlier Metabolic Pharmaceuticals Phase 1/2a work showing trends toward lipolytic activity; (3) post-2014 GRAS-status branding by supplement marketers that conflates safety determination with efficacy evidence. None of these are pivotal-trial outcomes.

The honest 2026 read: AOD-9604 has a preclinical lipolysis mechanism, a failed 24-week Phase 2b in 536 obese adults, an effectively shelved development program, a GRAS safety determination, and no published controlled-trial evidence of weight-loss efficacy. The "proven fat-loss peptide" framing inverts what the controlled-trial record actually shows.